A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Inclusion Criteria:

1. Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTRgenotype.

2. History of heart failure evidenced by at least 1 prior hospitalization for heartfailure or clinical evidence of heart failure without prior heart failurehospitalization manifested by signs or symptoms of volume overload or elevatedpressures or heart failure symptoms that required or requires ongoing treatment witha diuretic.

3. New York Heart Association Class I-III symptoms due to ATTR-CM.

4. On stable doses of cardiovascular medical therapy.

5. Completed ≥ 150 meters on the 6MWT on 2 tests prior to Day 1.

6. Left ventricular (LV) wall (interventricular septum or LV posterior wall) thickness ≥ 12 millimeters.

7. Biomarkers of myocardial wall stress: N-terminal pro-brain-type natriuretic pep (NT-proBNP) level ≥ 300 picograms/milliliter (pg/mL).

Exclusion Criteria:

1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization,or experienced stroke or transient ischemic attack within 90 days prior toscreening.

2. Hemodynamic instability at screening.

3. Likely to undergo heart transplantation within a year of screening.

4. Current treatment with marketed drug products and other investigational agents forthe treatment of ATTR-CM.

5. Current treatment with calcium channel blockers with conduction system effects (forexample, verapamil, diltiazem). The use of dihydropyridine calcium channel blockersis allowed.

6. Confirmed diagnosis of light-chain (AL) amyloidosis.

7. Biomarkers of myocardial wall stress: NT-ProBNP ≥ 8,500 pg/mL.

8. Measure of kidney function, estimated glomerular filtration rate by Modification ofDiet in Renal Disease formula < 30 mL/minute/1.73 meters squared.